Pre-made Elranatamab benchmark antibody ( Whole mAb, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.Elranatamab (PF-06863135) is a bispecific antibody (IgG2a) targeting the B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T cells, bridging them together to activate an immune response.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-663-1mg	1mg	Inquiry
GMP-Bios-ab-663-10mg	10mg	Inquiry
GMP-Bios-ab-663-100mg	100mg	Inquiry
GMP-Bios-ab-663-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Elranatamab
Target	TNFRSF17;CD3E
Format	Bispecific Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2;IgG2
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2021
Year Recommended	na
Companies	Pfizer
Conditions Approved	na
Conditions Active	Multiple myeloma
Conditions Discontinued	na
Development Tech	na